First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma.

Patrick Y WenTimothy F CloughesyAlan G OliveroKari M MorrisseyTimothy R WilsonXuyang LuLars U MuellerAlexandre F CoimbraBenjamin M EllingsonElizabeth GerstnerEudocia Q LeeJordi Rodon

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

GDC-0084 demonstrated classic PI3K/mTOR-inhibitor related toxicities. FDG-PET and concentration data from brain tumor tissue suggest that GDC-0084 crossed the blood-brain barrier.

Keyphrases

high grade
pet ct
positron emission tomography
endothelial cells
cell proliferation
pet imaging
multiple sclerosis
computed tomography
low grade
white matter
electronic health record
resting state
induced pluripotent stem cells
big data
functional connectivity